// App-Quantinova.ai

124 : Neoadjuvant and adjuvant, floxuridine, leucovorin, oxaliplatin, and docetaxel (FLOD) in patients with locally advanced operable gastroesophageal adenocarcinoma: A phase II study with pathologic responses and long term follow-up.

Researchers

Presenter

  • Bach Ardalan

Principal Investigators

  • Miriam Gombosh

  • Dido Franceschi

  • Eli Avisar

  • Danny Yakoub

  • Afonso Ribeiro

  • Jose Garrido

  • Nipun Merchant

  • Alan S Livingstone

Medical Centers

  • University of Miami, Miami, FL

  • Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

  • University of Miami Miller School of Medicine, Miami, FL

  • Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine and Jackson Memorial Hospital, Miami, FL

  • University of Miami, Miami, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

Biomarkers

  • N/A

Drug/Treatment

  • floxuridine

  • Oxaliplatin

  • leucovorin

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT00448760

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved